Results 51 to 60 of about 126,024 (329)

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BMC Cancer, 2018
Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications.
Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang   +9 more
doaj   +1 more source

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma

iScience, 2023
Summary: Sorafenib induces ferroptosis, making it a useful treatment against advanced liver hepatocellular carcinoma (LIHC). However, sorafenib resistance is extremely common among LIHC patients.
Mengxing Cai, Jingwen Luo, Chunxiu Yang, Xiaopeng Yang, Cheng Zhang, Lixin Ma, Yibin Cheng   +6 more
doaj   +1 more source

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. [PDF]

, 2016
Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options.
Alanis, Lourdes, Cho, Sung-Ki, Lee, Edward Wolfgang, Saab, Sammy   +3 more
core   +1 more source

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. [PDF]

, 2020
BackgroundTransforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib ...
Benhadji, Karim A, Cleverly, Ann, Estrem, Shawn T, Faivre, Sandrine, Gane, Ed, Giannelli, Gianluigi, Kelley, Robin K, Lahn, Michael M, Man, Michael, Paradis, Valerie, Raymond, Eric, Santoro, Armando, Smith, Claire, Wang, Shuaicheng   +13 more
core   +2 more sources

RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3‐mediated autophagy

EMBO Journal, 2020
N6‐methyladenosine (m6A) is an abundant nucleotide modification in mRNA, known to regulate mRNA stability, splicing, and translation, but it is unclear whether it is also has a physiological role in the intratumoral microenvironment and cancer drug ...
Ziyou Lin, Y. Niu, Arabella H Wan, Dongshi Chen, Heng-xing Liang, Xijun Chen, Lei Sun, Siyue Zhan, Liutao Chen, Chao Cheng, Xiaolei Zhang, Xianzhang Bu, Wei-ling He, Guohui Wan   +13 more
semanticscholar   +1 more source

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

Liver Cancer, 2022
Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS ...
M. Kudo, K. Ueshima, M. Ikeda, T. Torimura, N. Tanabe, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, T. Kuzuya, N. Isoda, M. Moriguchi, Hajime Aino, A. Ido, Naoto Kawabe, K. Nakao, Y. Wada, S. Ogasawara, K. Yoshimura, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, P. Johnson, Y. Arai   +26 more
semanticscholar   +1 more source

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]

, 2014
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip, Kaseb, Ahmed O, Kurzrock, Razelle, Tsimberidou, Apostolia M, Wolff, Robert A   +4 more
core   +3 more sources

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Liver Cancer, 2023
Introduction: Intratumoral administration of pexa-vec (pexastimogene devacirepvec), an oncolytic and immunotherapeutic vaccinia virus, given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses.
G. Abou-Alfa, Peter R. Galle, Yee Chao, J. Erinjeri, Jeong Heo, M. Borad, Angelo Luca, James M. Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, C. Breitbach, S. Qin, Edward Gane   +13 more
semanticscholar   +1 more source

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma

Cell Communication and Signaling, 2023
Background Sorafenib improves the overall survival in patients with advanced hepatocellular carcinoma (HCC). Dickkopf-1 (DKK1) is commonly overexpressed in HCC.
Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim   +12 more
doaj   +1 more source

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

Cancer Biology & Medicine, 2022
Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance.
Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen, Jinbao Liu   +12 more
doaj   +1 more source